|
A novel methodology to predict the response to HER2 bloking agent treatment in cancer |
|
Principal investigator : Gilles PAGES
|
|
CONTEXT
The
transmembrane receptor protein HER2 has a tyrosine kinase activity and is
involved in the regulation of several genes linked to the transcription of cell
cycle. HER2 is overexpressed in several types of cancer, as breast, ovary,
colon, pancreas…
This
protein is a well known target for anticancer treatments as Trastuzumab, a
monoclonal antibody, HER2 bloking agent.
HER2
positive breast cancer show different responses to a trastuzumab treatment. In
several cancer cases, Trastuzumab is not indicated to treat the tumor. Indeed,
medical centers try to adapt the treatment according to preliminary pronostic
on the response of each patient to a HER2 blocking agent treatment.
This prognostic
can be done by the characterization of each patient tumoral genes expression
profile, from 4 to 28 genes on tumor biopsy. This method is long, expensive and
implies a biopsy.
To read more, please register or connect in the right pannel... |
